Clinical Trials · NCT05048901
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- National Health Research Institutes, Taiwan
- Enrollment
- 49
- Start date
- Sep 2021
- Locations
- 11 sites, Taiwan
- Primary endpoint
- to determine the maximal tolerated dose of cabozantinib